Literature DB >> 11736944

Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia.

K Ogata1, N Yokose, Y Shioi, Y Ishida, J Tomiyama, H Hamaguchi, F Yagasaki, M Bessyo, H Sakamaki, K Dan, S Kuriya.   

Abstract

Debate exists over whether CD7 expression indicates an unfavourable prognosis in de novo acute myeloid leukaemia (AML). Meanwhile, the type of cytogenetics is a strong prognostic factor in AML. We analysed 256 de novo adult AML cases and found that the proportion of CD7+ cases increased stepwise from the cases with favourable cytogenetics to the cases with intermediate and unfavourable cytogenetics (3 out of 69 cases, 51 out of 140 cases and 25 out of 47 cases respectively, P < 0.0001). CD7-positivity adversely affected the survival only in the cases with unfavourable cytogenetics (P < 0.03). We recommend that CD7 expression in AML be interpreted in association with the cytogenetics.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11736944     DOI: 10.1046/j.1365-2141.2001.03139.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells.

Authors:  Nada Kraguljac Kurtović; Milena Krajnović; Andrija Bogdanović; Nada Suvajdžić; Jelica Jovanović; Bogomir Dimitrijević; Milica Colović; Koviljka Krtolica
Journal:  Med Oncol       Date:  2012-07-07       Impact factor: 3.064

2.  CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.

Authors:  Diogo Gomes-Silva; Erden Atilla; Pinar Ataca Atilla; Feiyan Mo; Haruko Tashiro; Madhuwanti Srinivasan; Premal Lulla; Rayne H Rouce; Joaquim M S Cabral; Carlos A Ramos; Malcolm K Brenner; Maksim Mamonkin
Journal:  Mol Ther       Date:  2018-10-04       Impact factor: 11.454

3.  Characterization of blasts in clinical samples containing few blasts.

Authors:  Hideya Hyodo; Kiyoyuki Ogata; Mikiko Tachibana; Kazuo Dan
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

4.  CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia.

Authors:  Xuanqi Cao; Haiping Dai; Qingya Cui; Zheng Li; Wenhong Shen; Jinlan Pan; Hongjie Shen; Qinfen Ma; Mengyun Li; Sifan Chen; Juncheng Chen; Xiaming Zhu; Huimin Meng; Lin Yang; Depei Wu; Xiaowen Tang
Journal:  Exp Hematol Oncol       Date:  2022-09-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.